Organic Chemical – Page 5

Intercept Withdraws Ocaliva from US Market After FDA Safety Concerns

2 months ago talkbio0Tagged Clinical Trials, concerns, Drug withdrawal syndrome, Injury of liver, Intercept Pharmaceuticals, Liver diseases, Ocaliva, Primary Biliary Cholangitis, regulatory setbacks, Safety, United States Food and Drug Administration

Intercept Pharmaceuticals; Ocaliva; liver disease; primary biliary cholangitis; FDA; drug withdrawal; safety concerns; liver injury; clinical trial hold; regulatory setbacks

Odyssey Therapeutics Secures $213M Series D to Accelerate Autoimmune Clinical Portfolio

2 months ago talkbio0Tagged Autoimmune Diseases, clinical pipeline, Immunoregulation, Inhibitor, investors, Odyssey, Precision - temporal, preclinical programs, Protac, RIPK2, Series D financing, Technology

Odyssey Therapeutics; Series D financing; $213 million; autoimmune diseases; clinical pipeline; preclinical programs; precision immunomodulation; RIPK2 inhibitor; PROTAC technology; investors

Lilly Opens AI Drug-Discovery Models to Biotechs for Free via TuneLab Platform

2 months ago talkbio0Tagged Antibodies, Artificial Intelligence, biotech startups, Drug Discovery, eli lilly, federated learning, Insitro, Machine Learning, Small Molecule, TuneLab

Eli Lilly; AI drug discovery; TuneLab; biotech startups; machine learning; small molecules; antibodies; data sharing; federated learning; Insitro

Novartis Acquires Tourmaline Bio for $1.4B to Bolster Cardiovascular Pipeline with Promising Phase 2 Drug

2 months ago talkbio0Tagged Acquisition, Anti-Inflammatory Agents, Antibodies, C-reactive protein, Cardiovascular Diseases, Chronic Kidney Diseases, interleukin-6, Novartis, pacibekitug, Phase 2 trial, Tourmaline Bio

Novartis; Tourmaline Bio; acquisition; $1.4 billion; pacibekitug; cardiovascular disease; anti-inflammatory; IL-6 antibody; ASCVD; phase 2 trial; C-reactive protein; chronic kidney disease

LB Pharmaceuticals Raises $285M in Upsized IPO to Fund Late-Stage Schizophrenia Drug Development

2 months ago talkbio0Tagged amisulpride, Approved, Central Nervous System Agents, Depression, Bipolar, IPO, LB-102, Pounds, Schizophrenia, United States Food and Drug Administration

LB Pharmaceuticals; IPO; schizophrenia; LB-102; amisulpride; Phase 3 clinical trial; bipolar depression; biotech fundraising; CNS drugs; FDA approval

LB Pharmaceuticals Files for $228M IPO to Fund Phase III Schizophrenia Drug

2 months ago talkbio0Tagged Alzheimer 's psychosis, amisulpride, Clinical Nurse Specialists, Depression, Bipolar, IPO, LB-102, Nasdaq, Phase 3 Clinical Trials, Pounds, Schizophrenia, United States Food and Drug Administration

LB Pharmaceuticals; IPO; Phase III trial; schizophrenia; LB-102; biotech; CNS therapeutics; bipolar depression; Alzheimer’s psychosis; amisulpride; FDA; Nasdaq

AstraZeneca Escalates EGFR Lung Cancer Rivalry with J&J: Tagrisso Combo Posts Survival Win

2 months ago talkbio0Tagged AstraZeneca, Combined, EGFR-mutated, FLAURA2 trial, Johnson & Johnson, Lazcluze, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Overall Survival, Pharmacotherapy, Rybrevant, Tagrisso

AstraZeneca; Tagrisso; EGFR-mutated NSCLC; Johnson & Johnson; Rybrevant; Lazcluze; Flaura2 trial; overall survival; lung cancer; chemotherapy combination

Novartis Again Partners with Argo Biopharma in $5.2B+ RNAi Cardiovascular Deal

2 months ago talkbio0Tagged ANGPTL3, Biopharma, biotech collaboration, cardiovascular pipeline, Drug Development, Dyslipidemias, milestone payments, Novartis, RNA Interference, RNA, Small Interfering

Novartis; Argo Biopharma; RNA interference (RNAi); siRNA; cardiovascular pipeline; ANGPTL3; dyslipidemia; biotech collaboration; drug development; milestone payments